ArticleWorld journal of clinical oncology2011
DNA damage and breast cancer.
Article in World journal of clinical oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Higher Levels ofMedical sciences (Basel, Switzerland) · 2026Article
- Nanotechnology-Driven Therapeutic Potential of Raloxifene in Osteoporosis and Cancer: A Recent Review.Current pharmaceutical design · 2026Review
- Review
- Signaling pathway dysregulation in breast cancer.Oncotarget · 2025Review
- Molecular docking analysis of breast cancer target RAC1B with ligands.Bioinformation · 2024Article
- Identification of cell subpopulations associated with disease phenotypes from scRNA-seq data using PACSI.BMC biology · 2023Article
- Progesterone from ovulatory menstrual cycles is an important cause of breast cancer.Breast cancer research : BCR · 2023Review
- Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration.International journal of molecular sciences · 2022Review
- Development of an adverse outcome pathway network for breast cancer: a comprehensive representation of the pathogenesis, complexity and diversity of the disease.Archives of toxicology · 2022Review
- A Dietary Antioxidant Formulation Ameliorates DNA Damage Caused by γ-Irradiation in Normal Human Bronchial Epithelial Cells In Vitro.Antioxidants (Basel, Switzerland) · 2022Article
- Review
- Article
- Pharmacological Assessment of the Antiprotozoal Activity, Cytotoxicity and Genotoxicity of Medicinal Plants Used in the Treatment of Malaria in the Greater Mpigi Region in Uganda.Frontiers in pharmacology · 2021Article
- Article
- THE INFLUENCE OF PERIODONTAL DISEASE TREATMENT ON 8-HYDROXY-DEOXYGUANOSINE CONCENTRATIONS IN SALIVA AND PLASMA OF CHRONIC PERIODONTITIS PATIENTS.Acta clinica Croatica · 2020Article
- Proteomics Profiling of KAIMRC1 in Comparison to MDA-MB231 and MCF-7.International journal of molecular sciences · 2020Article
- Elemental bioimaging shows mercury and other toxic metals in normal breast tissue and in breast cancers.PloS one · 2020Article
- Metallic air pollutants and breast cancer heterogeneity.Environmental research · 2019Article
- Data on Single Nucleotide Polymorphism of DNA Repair Genes and Breast Cancer Risk from Poland.Pathology oncology research : POR · 2019Article
- Polymorphism of DNA Repair Genes via Homologous Recombination (HR) in Ovarian Cancer.Pathology oncology research : POR · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is intimately related to the accumulation of DNA damage, and repair failures (including mutation prone repair and hyperactive repair systems). This article relates current clinical categories for breast cancer and their common DNA damage repair defects. Information is included on the potential for accumulation of DNA damage in the breast tissue of a woman during her lifetime and the role of DNA damage in breast cancer development. We then cover endogenous and exogenous sources of DNA damage, types of DNA damage repair and basic signal transduction pathways for three gene products involved in the DNA damage response system; namely BRCA1, BRIT1 and PARP-1. These genes are often considered tumor suppressors because of their roles in DNA damage response and some are under clinical investigation as likely sources for effective new drugs to treat breast cancers. Finally we discuss some of the problems of DNA damage repair systems in cancer and the conundrum of hyper-active repair systems which can introduce mutations and confer a survival advantage to certain types of cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.